✔ Oral LEVADOPA is the most common treatment
✔ Diminished therapeutic efficacy over time
✔ Levadopa is not a disease modifier
-Does not restore neuronal regeneration
-Alleviates dopamine levels temporarily
-Does not address cognitive decline
✔ Increase OFF episode over time
✔ Dyskinesia, and involuntary movements
✔ Intranasal LEVADOPA relieves OFF symptoms only, cost of $1000 for 1 to 2 weeks of dosing as prescribed
✔ Closes medical need gap for PD care
✔ Can complement standard PD care
✔ Expected to reduce PD motor symptoms, and cognitive decline
✔ Preclinical evidence: Does not cause resistance or OFF episodes
✔ Long lasting therapeutic effects (>5 weeks following last dose)
✔ CNS/CT-001 expected to be used for modest to severe PD
✔ Per kit: Up to $250 with de novo reagents + 9 dollars intranasal atomizers / month as OTC under 505 2b
✔ Transdermal option for CNS/CT-001 under co-development
